These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

564 related items for PubMed ID: 29642214

  • 1. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.
    Endo Y, Koga T, Suzuki T, Hara K, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Umeda M, Fukui S, Nishino A, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kuwana M, Kawakami A.
    Medicine (Baltimore); 2018 Apr; 97(15):e0436. PubMed ID: 29642214
    [Abstract] [Full Text] [Related]

  • 2. Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report.
    Endo Y, Koga T, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Umeda M, Fukui S, Nishino A, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kuwana M, Hosono Y, Mimori T, Kawakami A.
    Medicine (Baltimore); 2018 Jun; 97(26):e11024. PubMed ID: 29952940
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Fatal and extensive multiorgan hemorrhages in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: An autopsy case report.
    Watanabe T, Takizawa N, Nagasaka T, Nakamura Y, Ikai H, Yamamoto M, Murai Y, Takasugi K, Yokoyama-Kokuryo W, Fujita Y.
    Medicine (Baltimore); 2020 Jan; 99(3):e18600. PubMed ID: 32011440
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment.
    Shirakashi M, Nakashima R, Tsuji H, Tanizawa K, Handa T, Hosono Y, Akizuki S, Murakami K, Hashimoto M, Yoshifuji H, Ohmura K, Mimori T.
    Rheumatology (Oxford); 2020 Nov 01; 59(11):3284-3292. PubMed ID: 32276271
    [Abstract] [Full Text] [Related]

  • 6. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
    Sakamoto S, Okamoto M, Kaieda S, Fujimoto K, Nagata S, Tominaga M, Nakamura M, Zaizen Y, Nouno T, Koga T, Kawayama T, Kuwana M, Ida H, Hoshino T.
    Respir Investig; 2018 Nov 01; 56(6):464-472. PubMed ID: 30150008
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: A case series.
    Saito T, Mizobuchi M, Miwa Y, Sugiyama M, Mima Y, Iida A, Kanazawa N, Morikawa T, Hayashi J, Fukuda K, Shikida Y, Suzuki T, Honda H.
    J Clin Apher; 2021 Feb 01; 36(1):196-205. PubMed ID: 32823371
    [Abstract] [Full Text] [Related]

  • 9. Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: A case report.
    Ishikawa Y, Kasuya T, Fujiwara M, Kita Y.
    Medicine (Baltimore); 2020 Sep 11; 99(37):e21943. PubMed ID: 32925726
    [Abstract] [Full Text] [Related]

  • 10. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
    Hou J, Zhou ZX, Li JG, Xu YJ, Ding YC.
    Zhonghua Er Ke Za Zhi; 2019 Dec 02; 57(12):928-933. PubMed ID: 31795559
    [Abstract] [Full Text] [Related]

  • 11. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy.
    Abe Y, Kusaoi M, Tada K, Yamaji K, Tamura N.
    Rheumatology (Oxford); 2020 Apr 01; 59(4):767-771. PubMed ID: 31504956
    [Abstract] [Full Text] [Related]

  • 12. A case of anti-MDA5 antibody-positive dermatomyositis developing reversible cerebral vasospasm syndrome successfully treated by multi-immunosuppressant combination including mycophenolate mofetil.
    Muramatsu T, Tono T, Kanayama Y, Hasegawa Y, Kondo J, Hoshiyama T, Wada T, Arinuma Y, Tanaka S, Yamaoka K.
    Mod Rheumatol Case Rep; 2021 Jan 01; 5(1):69-75. PubMed ID: 32811369
    [Abstract] [Full Text] [Related]

  • 13. Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review.
    Nishi K, Ogura M, Tamai N, Gima M, Ide K, Koinuma G, Kamei K, Ito S.
    Pediatr Rheumatol Online J; 2022 Aug 04; 20(1):60. PubMed ID: 35927666
    [Abstract] [Full Text] [Related]

  • 14. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis.
    Horai Y, Koga T, Fujikawa K, Takatani A, Nishino A, Nakashima Y, Suzuki T, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Ida H, Kakugawa T, Sakamoto N, Ishimatsu Y, Mukae H, Hamaguchi Y, Fujimoto M, Kuwana M, Origuchi T, Kohno S, Kawakami A.
    Mod Rheumatol; 2015 Jan 04; 25(1):85-9. PubMed ID: 24716595
    [Abstract] [Full Text] [Related]

  • 15. Clinical utility of anti-Ro52 antibody confirmation in anti-MDA5 antibody-positive dermatomyositis: A case report.
    Kodera H, Hirano R, Akiyama M, Matsumoto Y.
    Mod Rheumatol Case Rep; 2024 Jul 08; 8(2):291-295. PubMed ID: 38753322
    [Abstract] [Full Text] [Related]

  • 16. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y, Fu Q, Wang R, Guo Q, Bao C.
    J Clin Lab Anal; 2019 Oct 08; 33(8):e22978. PubMed ID: 31301087
    [Abstract] [Full Text] [Related]

  • 17. Early Initiation of Plasma Exchange Therapy for Anti-MDA5+Dermatomyositis with Refractory Rapidly Progressive Interstitial Lung Disease.
    Sasaki N, Nakagome Y, Kojima A, Shimura K, Ishii A, Sugiyama M, Izumi Y, Hirano K, Kurabayashi T, Hosono Y, Yamada C, Sato S.
    Intern Med; 2024 Jan 15; 63(2):213-219. PubMed ID: 37225493
    [Abstract] [Full Text] [Related]

  • 18. Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody.
    Isoda K, Kotani T, Takeuchi T, Kiboshi T, Hata K, Ishida T, Otani K, Kamimori T, Fujiwara H, Shoda T, Makino S.
    Rheumatol Int; 2017 Aug 15; 37(8):1335-1340. PubMed ID: 28451794
    [Abstract] [Full Text] [Related]

  • 19. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
    Quintana-Ortega C, Remesal A, Ruiz de Valbuena M, de la Serna O, Laplaza-González M, Álvarez-Rojas E, Udaondo C, Alcobendas R, Murias S.
    Mod Rheumatol Case Rep; 2021 Jan 15; 5(1):101-107. PubMed ID: 33019894
    [Abstract] [Full Text] [Related]

  • 20. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review.
    González-Moreno J, Raya-Cruz M, Losada-Lopez I, Cacheda AP, Oliver C, Colom B.
    Rheumatol Int; 2018 Jul 15; 38(7):1293-1296. PubMed ID: 29417209
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.